Free Trial

UCB (OTCMKTS:UCBJF) Stock Passes Above 50-Day Moving Average - Time to Sell?

UCB logo with Medical background

Key Points

  • UCB SA's stock has crossed above its 50-day moving average of $231.36, trading at a high of $238.49 during recent sessions.
  • Analysts from Morgan Stanley have restated an "overweight" rating on UCB shares, contributing to an overall average rating of "Buy" from market data.
  • The company specializes in biopharmaceuticals for neurology and immunology diseases, with key products including Cimzia for inflammatory diseases and medications for epilepsy and Parkinson's disease.
  • MarketBeat previews top five stocks to own in November.

UCB SA (OTCMKTS:UCBJF - Get Free Report) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $231.36 and traded as high as $238.49. UCB shares last traded at $238.49, with a volume of 25 shares changing hands.

Analysts Set New Price Targets

Separately, Morgan Stanley restated an "overweight" rating on shares of UCB in a research report on Monday, September 8th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy".

Read Our Latest Analysis on UCB

UCB Trading Down 0.7%

The firm's fifty day moving average is $231.36 and its two-hundred day moving average is $196.56. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in UCB Right Now?

Before you consider UCB, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.

While UCB currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.